NR3C1 and Cowden syndrome 1: Recently, an Endocrine Society Clinical Practice Guideline for the treatment of CS has been published [2], the state of the art of medical therapy in CD extensively reviewed [3] and the use of adrenal blocking agents and glucocorticoid receptor blockers in hypercortisolemic states reappraised [4, 5].